Stericile Ltd is a chemical R&D company that has scientifically created a disinfectant meant to combat the epidemic of Hospital Acquired Infections. The company has achieved the biggest technological advancement in the peracetic acid market, having spent over £400,000 to create a unique chemical solution for the healthcare market. Stericile Ltd has secured a UK national supplier that caters to 15,000+ healthcare customers such as dentist & doctor surgeries, care homes, and medical centres with less effective products.
days to go:
Expired
investment:
£229,200
SuperCarers is an online platform that helps families to find trusted carers living in their local area. SuperCarers do not have the high overhead costs of agencies and therefore enable supercarers to be paid significantly more than the national living wage.
days to go:
Expired
investment:
£1,079,495
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments.
Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go:
Expired
investment:
Withheld
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors.
Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go:
Expired
investment:
£171,548
Please watch the video for more information
days to go:
Expired
investment:
£1,579,480
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings.
days to go:
Expired
investment:
£1,126,464
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices. Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.
days to go:
Expired
investment:
£167,910
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.
days to go:
Expired
investment:
£152,000
